	US 11,938,185 B2
	Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies
Maria-Cristina Loomis, Bothell, WA (US); Leon F. Garcia-Martinez, Woodinville, WA (US); Benjamin H. Dutzar, Seattle, WA (US); Daniel S. Allison, Lake Forest Park, WA (US); Katherine Lee Hendrix, Renton, WA (US); Ethan W. Ojala, Snohomish, WA (US); Pei Fan, Bothell, WA (US); Jeffrey T. L. Smith, Dublin (IE); John A. Latham, Seattle, WA (US); Charlie Karasek, Seattle, WA (US); Jenny Mulligan, Lake Forest Park, WA (US); Michelle Scalley-Kim, Seattle, WA (US); Erica Stewart, Seattle, WA (US); Vanessa Lisbeth Rubin, Seattle, WA (US); and Jens J. Billgren, Seattle, WA (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S, Valby (DK)
Filed on Dec. 15, 2020, as Appl. No. 17/122,243.
Application 17/122,243 is a division of application No. 16/787,260, filed on Feb. 11, 2020, granted, now 10,975,135.
Application 16/787,260 is a division of application No. 15/487,642, filed on Apr. 14, 2017, granted, now 10,913,783.
Claims priority of provisional application 62/408,347, filed on Oct. 14, 2016.
Claims priority of provisional application 62/366,902, filed on Jul. 26, 2016.
Claims priority of provisional application 62/322,939, filed on Apr. 15, 2016.
Claims priority of provisional application 62/322,957, filed on Apr. 15, 2016.
Claims priority of provisional application 62/323,495, filed on Apr. 15, 2016.
Claims priority of provisional application 62/323,573, filed on Apr. 15, 2016.
Prior Publication US 2021/0179688 A1, Jun. 17, 2021
Int. Cl. A61K 39/395 (2006.01); A61P 9/08 (2006.01); A61P 25/06 (2006.01); C07K 14/705 (2006.01); C07K 14/72 (2006.01); C07K 16/18 (2006.01); C07K 16/26 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01); C12N 5/07 (2010.01); C12N 15/09 (2006.01); C12N 15/63 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/22 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C07K 14/575 (2006.01)

CPC A61K 39/3955 (2013.01) [A61P 9/08 (2018.01); A61P 25/06 (2018.01); C07K 14/70503 (2013.01); C07K 14/72 (2013.01); C07K 16/18 (2013.01); C07K 16/26 (2013.01); C07K 16/28 (2013.01); C07K 16/2869 (2013.01); C07K 16/4241 (2013.01); C12N 5/06 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); G01N 33/6854 (2013.01); A61K 38/00 (2013.01); A61K 38/17 (2013.01); A61K 38/22 (2013.01); A61K 2039/505 (2013.01); A61K 48/00 (2013.01); C07K 14/47 (2013.01); C07K 14/575 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/575 (2013.01); Y02A 50/30 (2018.01)]

42 Claims

1. A method for blocking, inhibiting or neutralizing one or more biological effects associated with Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) and/or inhibiting PACAP-induced vasodilation and/or treating a condition associated with elevated PACAP, comprising administering to a subject in need thereof an effective amount of a humanized anti-PACAP antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1322 and a light chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1342,

wherein said heavy chain variable region comprises the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 1324, the heavy chain CDR2 polypeptide of SEQ ID NO: 1326, and the heavy chain CDR3 polypeptide of SEQ ID NO: 1328, and

said light chain variable region comprises the light chain CDR1 polypeptide of SEQ ID NO: 1344, the light chain CDR2 polypeptide of SEQ ID NO: 1346, and the light chain CDR3 polypeptide of SEQ ID NO: 1348,

and

wherein said subject has a condition associated with headache, migraine or photophobia.